- Home
- SONM vs BRTX Comparison
SONM vs BRTX Comparison
Compare SONM & BRTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SONM | BRTX |
|---|---|---|
| Founded | 1999 | 1997 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Telecommunications Equipment | Managed Health Care |
| Sector | Telecommunications | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.5M | 6.3M |
| IPO Year | 2019 | 2015 |
Fundamental Metrics
Financial Performance| Metric | SONM | BRTX |
|---|---|---|
| Price | $4.47 | $0.23 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 32.8K | ★ 1.3M |
| Earning Date | 04-14-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $58,298,000.00 | $81,000.00 |
| Revenue This Year | N/A | $298.39 |
| Revenue Next Year | N/A | $64.62 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.52 | $0.19 |
| 52 Week High | $12.30 | $2.04 |
Technical Indicators
Market Signals| Indicator | SONM | BRTX |
|---|---|---|
| Relative Strength Index (RSI) | 61.72 | 38.68 |
| Support Level | $2.66 | $0.23 |
| Resistance Level | $7.08 | $0.32 |
| Average True Range (ATR) | 0.45 | 0.02 |
| MACD | 0.19 | 0.00 |
| Stochastic Oscillator | 98.46 | 35.29 |
Price Performance
Historical ComparisonAbout SONM Sonim Technologies Inc.
DNA X Inc operates a digital asset management platform.
About BRTX BioRestorative Therapies Inc. (NV)
BioRestorative Therapies Inc is a biotechnology company based in the United States. It focuses on the development of regenerative medicine products and therapies using cell and tissue protocols, involving adult (non-embryonic) stem cells. The company's two core development programs include the Disc/Spine Program, which involves cell therapy candidate, BRTX-100, a product formulated from autologous cultured mesenchymal stem cells collected from the patient's bone marrow; and the Metabolic Program, which includes the development of cell-based therapy to target obesity and metabolic disorders using brown adipose-derived stem cells, to generate brown adipose tissue.